title: Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.
abstract: BACKGROUND
  Nelfinavir, an HIV protease inhibitor with numerous drug-drug interactions, is associated with dyslipidemia. Pravastatin is the preferred statin prescribed for HIV-associated dyslipidemia.
  
  
  OBJECTIVE
  To examine the effect of nelfinavir on pravastatin pharmacokinetics.
  
  
  METHODS
  Open-label study in healthy HIV-seronegative adults conducted at the AIDS Clinical Trials Group sites in the United States.
  
  
  METHODS
  Subjects received pravastatin 40 mg daily and underwent intensive sampling for pharmacokinetics on day 3. Subjects took only nelfinavir 1250 mg twice daily on days 4-12. On days 13-15, subjects continued nelfinavir and reinitiated pravastatin. Plasma samples were collected over 24 h for the calculation of pravastatin area under the concentration-time curve for 0-24 h on days 3 and 16.
  
  
  RESULTS
  Data from 14 subjects with complete pharmacokinetic samples were available for analysis. The median within-subject percentage change in pravastatin AUC was a decrease of 46.5%. Pravastatin maximum plasma concentrations were also lower when pravastatin was administered with nelfinavir. Median values for the maximum plasma concentrations were 27.9 and 12.4 ng/ml for days 3 and 16, respectively, and the median within-subject decrease was 40.1%.
  
  
  CONCLUSIONS
  Coadministration of pravastatin and nelfinavir led to a substantial reduction in pravastatin plasma concentrations. Higher doses of pravastatin may need to be prescribed in order to achieve optimal lipid-lowering activity.
authors.affiliation: New York University, New York, New York, USA. judith.aberg@med.nyu.edu
authors.forename: Judith A
authors.initials: JA
authors.lastname: Aberg
authors.forename: Susan L
authors.initials: SL
authors.lastname: Rosenkranz
authors.forename: Carl J
authors.initials: CJ
authors.lastname: Fichtenbaum
authors.forename: Beverly L
authors.initials: BL
authors.lastname: Alston
authors.forename: Susan W
authors.initials: SW
authors.lastname: Brobst
authors.forename: Yoninah
authors.initials: Y
authors.lastname: Segal
authors.forename: John G
authors.initials: JG
authors.lastname: Gerber
mesh_terms: D000328:Adult; D019540:Area Under Curve; D004334:Drug Administration Schedule; D004347:Drug Interactions; D005260:Female; D017320:HIV Protease Inhibitors / Q000097:blood / Q000493:pharmacokinetics*; D018023:HIV Seronegativity; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D019888:Nelfinavir / Q000097:blood / Q000493:pharmacokinetics*; D017035:Pravastatin / Q000097:blood / Q000493:pharmacokinetics*; D013997:Time Factors; D014838:Volunteers
chemical_list: D017320:HIV Protease Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019888:Nelfinavir; D017035:Pravastatin